Press Release
CF Foundation Awards Up to $2M to Eloxx for Additional Support for Studies into Nonsense Mutations Therapy
January 13, 2021
Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations.